Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Status:
Completed
Trial end date:
2021-06-22
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic
cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant
plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF
following autologous transplant as part of upfront treatment of multiple myeloma (MM). It is
hypothesized that the dendritic cell myeloma vaccine will result in improved response in
patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program